PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Muselaers, Stijn, Erdem, Selcuk, Bertolo, Riccardo, Ingels, Alexandre, Kara, Önder, Pavan, Nicola, Roussel, Eduard, Pecoraro, Angela, Marchioni, Michele, Carbonara, Umberto, Marandino, Laura, Amparore, Daniele, Campi, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999609/
https://www.ncbi.nlm.nih.gov/pubmed/35407435
http://dx.doi.org/10.3390/jcm11071829
Descripción
Sumario:Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.

Ejemplares similares